Michael P. Brown
0000-0002-5796-1932
Publication & Citation Trends
Publications
0 total
TMOD-20. Growth rates of patient-derived tumor organoids reflect glioblastoma patients’ heterogeneity in survival
Cited by 0
Semantic Scholar
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
Cited by 19
Semantic Scholar
Automating cancer registries: Pearls and pitfalls
Cited by 1
Semantic Scholar
CAR spacers: Not just filling space.
Cited by 1
Semantic Scholar
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
Cited by 3
Semantic Scholar
A tailored approach to horizon scanning for cancer medicines OA
Cited by 4
Semantic Scholar
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer OA
Cited by 8
Semantic Scholar
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors OA
Cited by 30
Semantic Scholar
Research Topics
CAR-T cell therapy research
(54)
Immunotherapy and Immune Responses
(51)
Organometallic Complex Synthesis and Catalysis
(48)
Cancer Immunotherapy and Biomarkers
(39)
Immune Cell Function and Interaction
(36)
Affiliations
Florida State University
South Australia Pathology
University of Iowa
Commonwealth Scientific and Industrial Research Organisation
St. Jude Children's Research Hospital